Kaiser Peter sold 2,967 shares of OCULAR THERAPEUTIX, INC at $8.20 for −$24.3k on May 26, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Development Officer
Chief Development Officer
Filed May 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$24,329.40Shares × reported price
Shares traded
2,967Common Stock
Price per share
$8.20Reported price. Read footnotes for ranges.
% of reported position traded
1.1%This security and ownership context
Holdings after
266,141Direct
Trade date
May 26, 2026Sell
Filed
May 28, 2026, 4:07 PM ET2-day reporting delay
Accession
0001104659-26-067483Code S · Transaction 386621
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 269,108 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

OCUL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
OCUL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +3.7%1w ago −13%1d ago −10%
Returns since7d −3.8%30d +7.5%90d +18%180d1y

Footnotes in full

F1: Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1549 to $8.2550, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.